title: The effects of L-arginine mono(2-mercaptoethanesulfonate) on the ischemic and reperfused heart.
abstract: We evaluated the effectiveness of L-arginine mono(2-mercaptoethanesulfonate) (argimesna) to limit the extent of myocardial damage resulting from 60 minutes of severe ischemia followed by 30 minutes of reperfusion in the Langendorff-perfused rabbit heart. Argimesna is a sulfhydryl group containing molecule which has no effect on glutathione status or on the total thiol pool. The effects of 10(-6) M argimesna were compared with those of 10(-6) M L-arginine and of 10(-6) M sodium salt of 2-mercaptoethanesulfonate (mesna). Pretreatment of the hearts with 10(-6) M argimesna resulted in marked myocardial protection, measured in terms of improved recovery of developed pressure (p less than 0.01), reduced release of creatine kinase (p less than 0.01), maintenance of mitochondrial function and increased stores of ATP on reperfusion (p less than 0.01). On reperfusion less oxidative stress developed, as indicated by less accumulation of oxidized glutathione (p less than 0.01). These effects were specific for argimesna; no significant protection could be found for mesna and L-arginine. The beneficial effects of argimesna could not be explained by hemodynamic differences or effects on anaerobic metabolism. Neither is it likely that argimesna acts as a free radical scavenger at the concentrations employed. The protection may be achieved by maintenance of -SH groups during ischemia and reperfusion.
authors.affiliation: Cattedra di Cardiologia, Spedali Civili, Brescia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Cargnoni
authors.forename: L
authors.initials: L
authors.lastname: Comini
authors.forename: A
authors.initials: A
authors.lastname: Boraso
authors.forename: F
authors.initials: F
authors.lastname: De Giuli
authors.forename: C
authors.initials: C
authors.lastname: Scotti
authors.forename: R
authors.initials: R
authors.lastname: Ferrari
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D003402:Creatine Kinase / Q000378:metabolism; D005609:Free Radicals; D005978:Glutathione / Q000378:metabolism; D007773:Lactates / Q000378:metabolism; D019344:Lactic Acid; D015080:Mesna / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008929:Mitochondria, Heart / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D010101:Oxygen Consumption / Q000187:drug effects; D010725:Phosphocreatine / Q000378:metabolism; D011817:Rabbits; D013438:Sulfhydryl Compounds / Q000378:metabolism
chemical_list: D005609:Free Radicals; D007773:Lactates; D013438:Sulfhydryl Compounds; D010725:Phosphocreatine; D019344:Lactic Acid; C059083:arginine 2-mercaptoethane sulfonate; D000255:Adenosine Triphosphate; D001120:Arginine; D003402:Creatine Kinase; D005978:Glutathione; D015080:Mesna